Showing 1 - 10 of 1,045
This paper compares the clinical trial strategies and performance of large, established ("mature") biopharmaceutical firms to those of smaller ("early stage") firms that have not yet successfully developed a drug. We study a sample of 235 cancer drug candidates that entered clinical trials...
Persistent link: https://www.econbiz.de/10012467754
We utilize a novel identification strategy to analyze the impact of assets in place on firms' decisions for future projects. We exploit the context in the pharmaceutical industry, where the loss of market exclusivity for a branded drug can be used to separate the impact of cash flows generated...
Persistent link: https://www.econbiz.de/10012481442
In 1996, following an epidemic, Pfizer tested a new drug on 200 children in Muslim Nigeria. 11 children died while others were disabled. We study the effects of the disclosure, in 2000, of the deaths of Muslim children in the Pfizer trials on vaccine compliance among Muslim mothers. Muslim...
Persistent link: https://www.econbiz.de/10014372412
Proposed "delinking" legislation would prohibit Pharmacy Benefit Managers (PBMs) from being remunerated based on the rebates and discounts they negotiate for drug insurance plans serving Medicare beneficiaries. This policy would significantly change drug pricing and utilization and shift...
Persistent link: https://www.econbiz.de/10014372424
We study the effect of price caps on the provision of costly effort by pharmaceutical firms using variation in drug discounts generated by a price regulation program that allows eligible hospitals to purchase outpatient drugs at steep discounts. These discounts directly affect drug...
Persistent link: https://www.econbiz.de/10014512103
We examine the role of consumption externalities in the demand for pharmaceuticals at both the brand level and over a …
Persistent link: https://www.econbiz.de/10012470978
We examine the role of network effects in the demand for pharmaceuticals at both the brand level and for a therapeutic …
Persistent link: https://www.econbiz.de/10012471776
We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and growth in lifetime per capita income. In both of the periods studied (1970-80 and 1980-91), there is a highly significant positive relationship across diseases between the increase...
Persistent link: https://www.econbiz.de/10012472240
I use variation in approval time for generic drugs to shed light on the objectives of the federal agency in charge of granting entry permission for these drugs (FDA). Applications belonging to firms later found to have engaged in fraud or corruption were approved nine months faster on average,...
Persistent link: https://www.econbiz.de/10012472670
to some non-Medicaid consumers of pharmaceuticals …
Persistent link: https://www.econbiz.de/10012473121